Inside Drug Pricing

CBO Relies On ICER, QALYs To Score Govt. Drug Price Negotiation

By John Wilkerson / February 8, 2021 at 2:05 PM

The Congressional Budget Office on Thursday (Feb. 4) revealed it relied heavily on metrics long opposed by drug makers and patient advocates to estimate the budget impact of Medicare price negotiation in House Democrats’ H.R. 3.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Inside Drug Pricing

CBO Relies On ICER, QALYs To Score Govt. Drug Price Negotiation

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.